Oxford, UK based Brainomix has developed an AI based platform that is designed to help hospitals diagnose the existence and severity of strokes from scans quickly as every minute counts

5 hours ago
1 min read

CEO Michalis Papadakis describes the technology and how it has the potential to greatly increase the number of people who experience stroke, and more quickly. The platform is FDA-cleared and CE-marked in Europe, and in wide use in Europe today. The company is also working on a lung fibrosis diagnostic.

Recent Posts

See All

Oxford, UK based Oxford BioTherapeutics has steadily been rolling out new partnerships, most recently with Bristol, Roche, and GSK, for its antibody and target discovery work

Oxford, UK based Sitryx has been busy lately with a deal announced with Boehringer Ingelheim, and its lead program targeting PKM2 in the clinic for atopic dermatitis

Novartis agreed to acquire London based Myricx Bio today for $1.1B up front and up to $400M in milestones. As Myricx's CEO tells us today at the company's HQ, this is all about novel ADC payloads

Oxford, UK based Brainomix has developed an AI based platform that is designed to help hospitals diagnose the existence and severity of strokes from scans quickly as every minute counts

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight